AbbVie Legacy Registry Study: Ulcerative Colitis
The purpose of this study is to evaluate the long-term safety of HUMIRA in moderately to severely active UC adult patients, 18 years of age and older, who are treated as recommended in the local product label. Patients being prescribed and treated with IMM (6-mercaptopurine (6-MP) or azathioprine (AZA)) with no concurrent biologic use will be considered the reference group. This is a registry study. We are being asked to follow enrolled patients during regular office visits at intervals determined by routine clinical practice. Patients will be asked to complete four brief quality of life surveys during each standard of care visit.